$WGS News

GeneDx: Why I Think The Worst Is Behind The Business

Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90

BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target

GeneDx Holdings Corp (WGS) (Q2 2026) Earnings Call Highlights: Record Volume and Early ...

GeneDx Holdings (NASDAQ:WGS) Beats Q2 Revenue Estimates and Swings to Adjusted Profit

GeneDx Q2 Earnings Call Highlights

GeneDx Holdings Corp. 2026 Q2 - Results - Earnings Call Presentation

GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript

GeneDx Reports Second Quarter 2026 Financial Results

CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate

GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $478.367M Est

GeneDx Holdings Corp. (WGS) Slid as Revenue Fell Short of Expectations

GeneDx Holdings Corp. (WGS) Fell Following a Significant Cut in 2026 Guidance

GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026

Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74

What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17%

Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63

Hedge Funder Eli Casdin Is Loading up on GeneDx Shares

GeneDx Holdings (WGS) Valuation After Q1 2026 Earnings Miss Guidance Cut And Legal Scrutiny

GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference